Answers are grounded in this paper and cite their sources.
Fabry disease is a rare X-linked lysosomal storage disorder caused by pathological mutations in the GLA gene which encodes α-galactosidase A (α-Gal A). The deficiency of α-Gal A leads to the accumulation of its substrates in multiple cell types, affecting various organs and resulting in a spectrum of clinical manifestations. Enzyme replacement therapy often falls short of adequately addressing the α-Gal A enzyme deficiency in critical tissues, highlighting the need for more efficacious interventions. Here, we present EXG110, an AAV-based gene therapy, engineered to enable robust and durable α-Gal A expression. EXG110 comprises a codon-optimized human GLA transgene, a synthetic dual-tissue promoter for hepatocyte and myocyte expression, and an engineered AAV9 capsid variant for efficient liver and muscle transduction. In both adult and juvenile Fabry mice, a single intravenous dose of EXG110 achieved supraphysiological plasma α-Gal A activity and near-complete clearance of accumulated substrates in key tissues. EXG110-treated juvenile Fabry mice exhibited sustained α-Gal A activity for at least 12 weeks, with the highest vector genome retention in the heart. Adult non-human primates (NHPs) treated with EXG110 showed dose-dependent plasma α-Gal A activity persisting for at least 26 weeks. These results provide proof of concept for treating Fabry disease with EXG110.
No takes yet. Share an insight, caveat, or question.
Li et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: